On the one hand, FXYD1 was downregulated in almost all cancers indicating a promising pan‐cancer biomarker in the future, while FXYD2‐FXYD5 failed to exhibit the specific tendency in gliomas compared with other cancers (Figure S2). Here, FXYD1 is linked to central nervous system cancer.